Improving Drug Abuse Treatment by Research and Training

描述：(申请人提供)本K-05提案的总体目标是支持和扩展申请人的 发展和改进药物治疗和心理治疗的工作 药物滥用以及指导科学家开始这样的职业生涯。这个 申请者在这两个领域都有富有成效的职业生涯，开发这样的项目 先是在耶鲁，现在在哥伦比亚。在他在哥伦比亚大学的八年里， 申请人除从事上述活动外，还担任过执行副总裁 他和约瑟夫是政策研究中心CASA的总裁兼医学主任 Califano成立于1992年。获得K05奖将提供资金 对候选人的支持，以便他可以放弃他的CASA职位 其行政职责和政策研究，并致力于他的全部时间 医学院的生物医学研究和培训。 申请人目前的研究有两个主要主题：1)治疗阿片类药物 戒毒，2)发展和改进药物和行为方法 治疗可卡因、海洛因和大麻依赖。目前的资金用于 在本奖项的头三年，这些领域都在掌握之中。申请人 将指导一项比较麻醉快速阿片类药物解毒(Arod)和 丁丙诺啡快速阿片脱毒为可乐定辅助阿片脱毒。这个 Arod的受欢迎程度还没有通过对技术的评估来匹配，Side 效果和长期随访。这是第一个这样做的对照研究。 此外，申请者将被派在哥伦比亚NIDA多站点的站点 洛非西定是一种α-肾上腺素能激动剂，可能会有更好的治疗效果 疗效优于可乐定，他的中心将进行一项新的门诊试验 纳曲酮仓库。同样专注于拮抗剂治疗的是第二阶段试验，在该试验中 他是联合调查员，测试一种新开发的手动心理疗法 纳曲酮维持的个体，这也将是第一项测试 新的Depot纳曲酮在临床研究中的有效性。药物治疗 发展研究中心，在那里他是PI，专注于瞄准 瘾君子以及开发和/或利用模型来改进测试 潜在的药物。它包括人体对海洛因的实验室研究，PET 成像，一项针对可卡因的大规模药物试验，并测试潜力 治疗大麻戒断和渴求的药物。此外，申请人 计划增加他指导年轻科学家的时间，包括他的研究员 培训补助金以及年轻教职员工。更多的时间也将花在 加强与哥伦比亚大学和哥伦比亚大学其他研究人员的合作研究 开发新的药物开发项目。

DESCRIPTION: (Provided by Applicant) The overall aim of this K-05 proposal is to support and expand the applicant's work in developing and improving pharmacotherapy and psychotherapy for substance abuse as well as mentoring scientists embarking on such a career. The applicant has had a productive career in both areas, developing such programs first at Yale and currently at Columbia. During his eight years at Columbia the applicant has, in addition to these activities, served as Executive Vice President and Medical Director of CASA, a policy research center he and Joseph Califano founded in 1992. Receiving the K05 award would provide financial support for the candidate so that he could relinquish his CASA position with its administrative duties and policy research, and devote himself full time to biomedical research and training at the medical school. The applicant's current research has two major themes: 1) treating opioid withdrawal, 2) developing and improving medications and behavioral approaches for treating cocaine, heroin and marijuana dependence. Current funding for these areas is in hand for the first three years of this award. The applicant will direct a study comparing Anesthesia Rapid Opioid Detox (AROD) to Buprenorphine Rapid Opioid Detox to Clonidine Assisted Opioid Detox. The popularity of AROD has not been matched by evaluation of the technique, side effects and long term follow-up. This is the first controlled study to do so. In addition, the applicant will be PI at the Columbia site of a NIDA multi-site phase III trial of lofexidine, an alpha-adrenergic agonist with possible better efficacy than clonidine, and his Center will run an outpatient trial of a new Depot Naltrexone. Also focused on antagonist therapy is a Stage II Trial where he is Co-Investigator, testing a newly developed manualized psychotherapy for naltrexone-maintained individuals, which will also be the 1st study to test the usefulness of the new Depot Naltrexone in a clinical study. The Medication Development Research Center, where he is PI, focuses on targeting subgroups of addicts as well as development and/or utilization of models to improve testing potential medications. It includes human laboratory research on heroin, PET imaging, a large scale medication trial for cocaine, and testing potential medications for marijuana withdrawal and craving. In addition, the applicant plans to expand his time mentoring young scientists, including fellows on his training grant as well as young faculty. Additional time would also be spent in increasing collaborative research with other investigators at Columbia and developing new medication development projects.